← All trials
NCT03076970
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 21, 2017
- Primary completion
- Apr 13, 2017
- Completion date
- Apr 13, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 42
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- CoLucid PharmaceuticalsLead sponsor
- Shin Nippon Biomedical LaboratoriesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.